These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 26506740)

  • 1. DENGUE VACCINES.
    Thisyakorn U; Thisyakorn C
    Southeast Asian J Trop Med Public Health; 2015; 46 Suppl 1():138-45. PubMed ID: 26506740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targets and strategies for vaccine development against dengue viruses.
    Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
    Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of dengue virus and the development of a vaccine.
    Murrell S; Wu SC; Butler M
    Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue virus vaccine development.
    Yauch LE; Shresta S
    Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines licensed and in clinical trials for the prevention of dengue.
    Torresi J; Ebert G; Pellegrini M
    Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
    Guy B; Jackson N
    Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.
    Chu H; George SL; Stinchcomb DT; Osorio JE; Partidos CD
    J Infect Dis; 2015 Nov; 212(10):1618-28. PubMed ID: 25943203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latest developments and future directions in dengue vaccines.
    Thisyakorn U; Thisyakorn C
    Ther Adv Vaccines; 2014 Jan; 2(1):3-9. PubMed ID: 24757522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
    Guy B; Briand O; Lang J; Saville M; Jackson N
    Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey.
    Ravel G; Mantel N; Silvano J; Rogue A; Guy B; Jackson N; Burdin N
    Vaccine; 2017 Oct; 35(43):5918-5923. PubMed ID: 28882438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current progress in dengue vaccines.
    Wan SW; Lin CF; Wang S; Chen YH; Yeh TM; Liu HS; Anderson R; Lin YS
    J Biomed Sci; 2013 Jun; 20(1):37. PubMed ID: 23758699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.